Market assessment for glucose-responsive microgels and microneedle patch technology

葡萄糖反应性微凝胶和微针贴片技术的市场评估

• 批准号: 536712-2019
• 负责人: Wu, XiaoYu
• 金额: $ 1.09万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=668990
• 关键词: Market; assessment; glucose; responsive; microgels

Our laboratory has invented a glucose-responsive device that can sense glucose levels and release native glucagon in real time in response to hypoglycemia. The device is a composite transdermal microneedle patch comprising a microneedle array and embedded microgel particles. The microparticles are made from three types of monomers - one provides glucose-responsive volume change, one for stabilizing native glucagon, and one for facilitating glucagon encapsulation. After the microneedle patch is applied, the microneedles penetrate the skin, swell quickly in the body fluid, and enable the microgels in contact with the fluid and glucose. The microgels sense the glucose concentrations and shrink at low glucose levels thus squeezing the encapsulated glucagon out. As a result, the glucagon diffuses out of the needles to the blood circulation and to the liver thereby increasing blood glucose levels. The entire process automatically proceeds without external intervention of patients or care givers. The invented microgel system can maintain the native structure and bioactivity of glucagon at body temperature and under the conditions of making microneedle array. In a T1D rat model, our laboratory has demonstrated that the transdermal patch is able to prevent hypoglycemia induced by excess insulin administration for up to 3 hours. This technology is the topic of US Provisional Patent 62/757,677 filed on 11/08/2018 - "Device and Its Use for Preventing Hypoglycemia". To commercialize these proprietary technologies into a product, Innovations and Partnerships Office (IPO) has contracted a consultant company to perform market analysis to address various market aspects. At the completion of the project, the company will provide a report which will guide us next move of commercialization activities including application for an NSERC I2I Phase 1 grant to optimize the composition and design of the device and develop larger scale methods. These activities will strengthen our position of attracting strategic development partners and investors in future.

我们的实验室已经发明了一种葡萄糖响应装置，可以感应葡萄糖水平并在低血糖时真实的时间释放天然胰高血糖素。所述装置是包含微针阵列和嵌入的微凝胶颗粒的复合经皮微针贴剂。微粒由三种类型的单体制成-一种提供葡萄糖响应性体积变化，一种用于稳定天然胰高血糖素，一种用于促进胰高血糖素包封。贴上微针贴片后，微针穿透皮肤，在体液中迅速膨胀，使微凝胶与体液和葡萄糖接触。微凝胶感测葡萄糖浓度并在低葡萄糖水平下收缩，从而将包封的胰高血糖素挤出。结果，胰高血糖素从针头扩散到血液循环和肝脏，从而增加血糖水平。整个过程自动进行，无需患者或护理人员的外部干预。本发明的微凝胶系统在体温和微针阵列制备条件下，能保持胰高血糖素的天然结构和生物活性。在T1 D大鼠模型中，我们的实验室已经证明透皮贴剂能够预防过量胰岛素给药诱导的低血糖长达3小时。该技术是2018年8月11日提交的美国临时专利62/757，677-“Device and Its Use for Preventing Hypoprosthesis”的主题。为了将这些专利技术商业化为产品，创新和伙伴关系办公室已与一家咨询公司签订合同，由其进行市场分析，以解决市场的各个方面。在项目完成后，该公司将提供一份报告，指导我们下一步的商业化活动，包括申请NSERC I2 I第1阶段拨款，以优化设备的组成和设计，并开发更大规模的方法。这些活动将加强我们在未来吸引战略发展伙伴和投资者的地位。